Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 4:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 99 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neonates and Term Infants Clear all
Completed Phase 4 Interventional Results available

Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

NCT01519661
View directory record Official record
Conditions
Pulmonary Infections, Pseudomonas Aeruginosa in Cystic Fibrosis
Interventions
TBM100
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
20
States / cities
Little Rock, Arkansas • Denver, Colorado • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2015 · Synced Jul 23, 2026, 4:32 AM EDT
Not yet recruiting Phase 3 Interventional

Safety and Efficacy of Fetoscopic Endoluminal Tracheal Occlusion in Congenital Diaphragmatic Hernia

NCT06946576
View directory record Official record
Conditions
Congenital Diaphragmatic Hernia
Interventions
Fetoscopic Endoluminal Tracheal Occlusion (FETO) Procedure
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 1, 2025 · Synced Jul 23, 2026, 4:32 AM EDT
Completed Phase 2 Interventional Results available

Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 (Sebelipase Alfa) in Adult Subjects With Lysosomal Acid Lipase Deficiency

NCT01488097
View directory record Official record
Conditions
Cholesterol Ester Storage Disease (CESD), Lysosomal Acid Lipase Deficiency, LAL-Deficiency
Interventions
sebelipase alfa
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
5
States / cities
Eureka, California • Sacramento, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Jul 23, 2026, 4:32 AM EDT
Terminated No phase listed Observational

Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants

NCT04506619
View directory record Official record
Conditions
Retinopathy of Prematurity (ROP), Intraventricular Hemorrhage, Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity
Interventions
No Intervention
Other
Lead sponsor
Oak Hill Bio Ltd
Industry
Eligibility
12 Months to 24 Months
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
South Bend, Indiana • Jackson, Mississippi • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Jul 23, 2026, 4:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prediction of Jaundice in Term Infants

NCT01203410
View directory record Official record
Conditions
Infant, Newborn, Jaundice
Interventions
Not listed
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 8 Hours
Enrollment
535 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1991 – 1992
U.S. locations
13
States / cities
Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Jul 23, 2026, 4:32 AM EDT
Completed Phase 1 Interventional Results available

Gadobutrol Pharmacokinetic and Safety Study in Pediatric Subjects Aged <2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive)

NCT01544166
View directory record Official record
Conditions
Magnetic Resonance Imaging
Interventions
Gadobutrol (Gadavist, BAY86-4875)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Up to 2 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Savannah, Georgia • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2020 · Synced Jul 23, 2026, 4:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Time Outside Target Oxygen Saturation Range in Preterm Infants and Long Term Outcomes and Preterm Infants

NCT00845624
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
1 Day to 12 Months
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 14, 2012 · Synced Jul 23, 2026, 4:32 AM EDT
Completed Not applicable Interventional

Donor Breast Milk and Breastfeeding Rates

NCT04572581
View directory record Official record
Conditions
Breastfeeding, Exclusive, Breastfeeding
Interventions
Donor Breast Milk
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Up to 3 Days
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2022 · Synced Jul 23, 2026, 4:32 AM EDT
Completed Phase 2 Interventional Results available

Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia

NCT00477594
View directory record Official record
Conditions
Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant, Hyperlipidemias, Metabolic Diseases, Hyperlipoproteinemia Type II, Metabolism, Inborn Errors, Genetic Diseases, Inborn, Infant, Newborn, Diseases, Metabolic Disorder, Congenital Abnormalities, Hypercholesterolemia, Hyperlipoproteinemias, Dyslipidemias, Lipid Metabolism Disorders
Interventions
mipomersen sodium
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
12 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
5
States / cities
Chicago, Illinois • Auburn, Maine • Biddeford, Maine + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2016 · Synced Jul 23, 2026, 4:32 AM EDT
Completed Phase 4 Interventional

Inhaled Nitric Oxide by Oxygen Hood in Neonates

NCT00732537
View directory record Official record
Conditions
Respiratory Failure, Infant, Persistent Fetal Circulation
Interventions
inhaled Nitric Oxide, Oxygen (>90% by hood) - standard therapy
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Hour to 1 Week
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 11, 2008 · Synced Jul 23, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation

NCT01946412
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
2 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
12
States / cities
Birmingham, Alabama • Denver, Colorado • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Jul 23, 2026, 4:32 AM EDT
Completed Phase 1 Interventional

A Pharmacokinetics, Pharmacodynamics and Safety Study of Rabeprazole in New Born Infants With Gastroesophageal Reflux Disease (GERD)

NCT00855361
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Rabeprazole sodium
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Up to 44 Weeks
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
10
States / cities
Orange, California • Washington D.C., District of Columbia • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2013 · Synced Jul 23, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

NCT03125395
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
LUM/IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
2 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
17
States / cities
Palo Alto, California • Aurora, Colorado • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Jul 23, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis

NCT01931839
View directory record Official record
Conditions
Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
Interventions
Lumacaftor Plus Ivacaftor Combination, Ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
1,164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
91
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Jul 23, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age

NCT05856227
View directory record Official record
Conditions
Neonatal Sepsis
Interventions
Ceftobiprole medocaril
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
3 Days to 3 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Evanston, Illinois • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Jul 23, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

Long Term Administration of Inhaled Mannitol in Cystic Fibrosis

NCT00630812
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
inhaled mannitol, Placebo comparator
Drug
Lead sponsor
Syntara
Industry
Eligibility
6 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
28
States / cities
Tucson, Arizona • Hartford, Connecticut • Jacksonville, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Jul 23, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

NCT04058366
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
ELX/TEZ/IVA, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
33
States / cities
Tucson, Arizona • Long Beach, California • Palo Alto, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2024 · Synced Jul 23, 2026, 4:32 AM EDT
Active, not recruiting Not applicable Interventional

Infant Survival and Long-term Outcome Following Fetoscopic Endoluminal Tracheal Occlusion in Severe Left and Right Congenital Diaphragmatic Hernia, A Phase III Trial

NCT06179472
View directory record Official record
Conditions
Congenital Diaphragmatic Hernia
Interventions
BALT GOLDBAL2 Balloon
Device
Lead sponsor
Inna Lobeck
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jul 23, 2026, 4:32 AM EDT
Completed Phase 1 Interventional

Neonatal Erythropoietin in Asphyxiated Term Newborns

NCT00719407
View directory record Official record
Conditions
Hypoxic-ischemic Encephalopathy
Interventions
erythropoietin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 24 Hours
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 8, 2012 · Synced Jul 23, 2026, 4:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Growth, Safety, and Efficacy of an Infant Formula for Healthy Term Infants

NCT04218929
View directory record Official record
Conditions
Infants, Newborn
Interventions
Study Formula (SF), Comparator Formula (CF)
Other
Lead sponsor
ByHeart
Industry
Eligibility
0 Days to 14 Days
Enrollment
311 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
27
States / cities
Birmingham, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Jul 23, 2026, 4:32 AM EDT
Recruiting No phase listed Observational

Cerebral/ Cortical Visual Impairment: Screening, Identification and Outcome Prediction in Neonates

NCT07275021
View directory record Official record
Conditions
Preterm Less Than 32wks With IVH, WMI/PVL, Late Preterm or Term (37-42wks) With Neonatal Encephalopathy Treated With Hypothermia for HIE
Interventions
Prospective Clinical and Neurodevelopmental Data Collection
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
31 Weeks to 42 Weeks
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Jul 23, 2026, 4:32 AM EDT
Completed No phase listed Observational Results available

Long-Term Effects of Hydroxyurea in Children With Sickle Cell Anemia (The BABY HUG Follow-up Study)

NCT00890396
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
Hydroxyurea
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 7 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
14
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Jul 23, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Trial of Inhaled Mannitol in Adult Cystic Fibrosis Subjects

NCT02134353
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Inhaled mannitol, Placebo Comparator: Arm B - Control
Drug
Lead sponsor
Syntara
Industry
Eligibility
18 Years to 99 Years
Enrollment
423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
36
States / cities
Mobile, Alabama • Tucson, Arizona • Little Rock, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Jul 23, 2026, 4:32 AM EDT
Terminated Phase 4 Interventional

Inhaled Iloprost for the Treatment of Persistent Pulmonary Hypertension in the Term and Near Term Infants.

NCT00409526
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Inhaled Iloprost
Drug
Lead sponsor
University of Chicago
Other
Eligibility
Up to 7 Days
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 1, 2014 · Synced Jul 23, 2026, 4:32 AM EDT